Safety of Tacrolimus in Autoimmune Disease: Results From Post-marketing Surveillance in South Korea

OBJECTIVE: Tacrolimus, a macrolide immunosuppressant, is approved in Korea for the treatment of rheumatoid arthritis (RA), lupus nephritis (LN) and myasthenia gravis (MG) We report three prospective post-marketing surveillance studies of tacrolimus conducted in South Korea in these indications METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Wan-Hee, Lee, Sang-Il, Kim, Tae-Hwan, Sung, Jung-Joon, Kim, Seung Min, Hua, Fan, Sumarsono, Budiwan, Park, Sung Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Rheumatology 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324909/
https://www.ncbi.nlm.nih.gov/pubmed/37476363
http://dx.doi.org/10.4078/jrd.2021.28.4.202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324909/
https://www.ncbi.nlm.nih.gov/pubmed/37476363
http://dx.doi.org/10.4078/jrd.2021.28.4.202

Ejemplares similares